Retrospective Analysis of Venetoclax Combined with Azacitidine Compared with "3+7" or Similar Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.03.008
- Author:
Lu-Lu WANG
1
;
Juan ZHANG
1
;
Yue ZHANG
1
;
Yong ZHANG
1
;
Xiao-Min DONG
1
;
Dan-Yang ZHANG
1
;
Ting-Ting CHEN
1
;
Yun-Hui ZHOU
1
;
Teng WANG
1
;
Hui-Ling LAN
1
;
He-Bing ZHOU
1
Author Information
1. Department of Hematology, Luhe Teaching Hospital of Capital Medical University, Beijing 101100, China.
- Publication Type:English Abstract
- Keywords:
acute myeloid leukemia;
venetoclax;
azacitidine
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Retrospective Studies;
Sulfonamides/administration & dosage*;
Azacitidine/administration & dosage*;
Bridged Bicyclo Compounds, Heterocyclic/administration & dosage*;
Aged;
Middle Aged;
Male;
Female;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2025;33(3):672-681
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To retrospectively analyze the clinical data of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax combined with azacitidine (Ven/Aza) or standard "3+7" regimen and similar regimens, collect real-world study data, compare the treatment response and adverse events between the two regimens, as well as perform survival analysis.
METHODS:To retrospectively analyze the efficacy, survival, and adverse reactions of newly diagnosed AML patients treated with Ven/Aza (24 cases) and "3+7" regimens (117 cases ) in our hospital from September 2009 to March 2023, as well as factors influencing outcomes. A propensity score matching (PSM) was performed on age and Eastern Cooperative Oncology Group performance status (ECOG PS) to obtain a 1:1 matched cohort of 20 pairs, and the efficacy and survival before and after the matching were compared.
RESULTS:The median age of patients in the Ven/Aza group was 69 years, while that in the "3+7" group was 56 years (P <0.001). Objective remission rate (ORR) was 62.5% in Ven/Aza group and 74.8% in "3+7" group (P >0.05). The median overall survival (OS) in the Ven/Aza group was 522 days, while that in the "3+7" group was 1 002 days (P >0.05). After controlling the two variables of age and ECOG PS, a PSM cohort of 20 pairs was obtained, in which the ORR was 65% in Ven/Aza group and 60% in "3+7" group (P >0.05). The median OS was 522 days and 629 days, and median progression-free survival (PFS) was 531 days and 198 days between the two groups, respectively. There were no statistically significant differences in OS and PFS between the two groups (both P >0.05). Additionally, the incidence of adverse events in the Ven/Aza group was significantly reduced.
CONCLUSION:The overall cohort shows that the "3+7" regimen has advantages in efficacy and survival, but Ven/Aza regimen is relatively safer. After performing PSM on age and ECOG PS, the Ven/Aza group showed improved efficacy, and a longer median PFS compared to "3+7" group.
